This study focuses on patients with moderate to severe Crohn’s disease, which is a chronic inflammatory condition affecting the digestive tract. The research evaluates a new medication called SAR442970, which is given as an injection under the skin. The study aims to determine how well different doses of this medication work in improving the condition of the intestinal lining in people with Crohn’s disease.

The study compares SAR442970 with placebo in patients who have not responded well enough to previous treatments. The medication or placebo will be administered through subcutaneous injections, which means the medicine is given under the skin. The maximum daily dose of the medication will be 150 milligrams, with a total maximum dose of 300 milligrams over the course of treatment.

The treatment period lasts for 52 weeks, during which patients will receive either the study medication or placebo. Throughout the study, doctors will monitor the condition of the intestinal lining and track various symptoms of Crohn’s disease. They will also check how safe the medication is and how well patients tolerate it. Participants will have regular check-ups to assess their response to treatment and monitor for any side effects.